药物研究动态

　　[摘要] 随着对降糖药不良反应和降糖外保护效应的重视不断提高，基于肠促胰素治疗药物的临床应用不断增加。同样作为基于肠促胰素治疗的药物，胰升血糖素样肽-1(GLP-1)受体激动剂与二肽基肽酶-4(DPP-4)抑制剂在药理学、疗效和安全性方面存在一些差异，且不同的GLP-1受体激动剂和DPP-4抑制剂间也各有优势和不足。本文将以在中国或亚洲患者中进行的研究为证据，对在我国上市的2种GLP-1受体激动剂和5种DPP-4抑制剂的降糖疗效、降糖外保护效应进行比较，目的是指导临床医生根据患者具体情况，选择合理的降糖药物。

　　[关键词] 糖尿病,2型;肠促胰素

　　[Summary] Physicians are paying more attention to adverse effects and protection beyond hypoglycemic effects of antidiabetic drugs, and the application of incretin-based drugs in our country is increasing. But in all the available incretin-based drugs, there is some differences in pharmacology, efficacy and safety between GLP-1 receptor agonists and DPP-4 inhibitors. Even within GLP-1 receptor agonists and DPP-4 inhibitors subclass, different drugs have their own advantages and disadvantages. This paper will present studies conducted in China or Asian patients as evidence to compare hypoglycemic effects and protection beyond hypoglycemic effects of current available incretin-based drugs. The aim is to guide clinicians in selecting optimal antidiabetic drugs based on patients’ specific condition.

　　[Key words] Diabetes mullitus, type 2 ; Incretin